Literature DB >> 6375682

Lymphocytes in the skin of patients with progressive systemic sclerosis. Quantification, subtyping, and clinical correlations.

A D Roumm, T L Whiteside, T A Medsger, G P Rodnan.   

Abstract

Mononuclear cells (MNC) present in the dermis of the forearm and in the blood of patients with progressive systemic sclerosis (PSS) were quantified and analyzed for subsets using monoclonal antibodies. The findings were correlated with cutaneous and systemic features of the disease. Total T lymphocytes and their subsets, B cells, and macrophages were enumerated in the skin samples of 21 patients with PSS. The dermal MNC infiltrates consisted mostly of activated T lymphocytes with a mean T helper/T suppressor (T4/T8) ratio of 2.4 +/- 1.3 SD. Few B1-positive or T6-positive cells (macrophages) were observed. There was no correlation between the skin or blood T4/T8 ratios and the degree of skin thickening. On histologic examination, 58 of 115 (50%) untreated patients with PSS had prominent dermal MNC infiltration. Significant correlations between the degree of MNC infiltration and both the degree (P less than 0.05) and progression (P less than 0.05) of skin thickening were observed. No correlations with other systemic disease features of PSS were noted. These results suggest that cutaneous T lymphocytes may play a role in mediating dermal sclerosis in PSS.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375682     DOI: 10.1002/art.1780270607

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  103 in total

Review 1.  Bone marrow transplantation in the treatment of systemic sclerosis.

Authors:  F Viganego; R Nash; D E Furst
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 2.  The Th1/Th2 paradigm in the pathogenesis of scleroderma, and its modulation by thalidomide.

Authors:  S J Oliver
Journal:  Curr Rheumatol Rep       Date:  2000-12       Impact factor: 4.592

Review 3.  T lymphocyte and fibroblast interactions: the case of skin involvement in systemic sclerosis and other examples.

Authors:  C Chizzolini
Journal:  Springer Semin Immunopathol       Date:  1999

4.  Elevated serum L-selectin levels and decreased L-selectin expression on CD8(+) lymphocytes in systemic sclerosis.

Authors:  Y Shimada; M Hasegawa; K Takehara; S Sato
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

5.  Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation.

Authors:  G Valentini; A Baroni; K Esposito; C Naclerio; E Buommino; A Farzati; G Cuomo; B Farzati
Journal:  J Clin Immunol       Date:  2001-05       Impact factor: 8.317

6.  Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease.

Authors:  M Binks; J R Passweg; D Furst; P McSweeney; K Sullivan; C Besenthal; J Finke; H H Peter; J van Laar; F C Breedveld; W E Fibbe; D Farge; E Gluckman; F Locatelli; A Martini; F van den Hoogen; L van de Putte; A V Schattenberg; R Arnold; P A Bacon; P Emery; I Espigado; B Hertenstein; F Hiepe; A Kashyap; I Kötter; A Marmont; A Martinez; M J Pascual; A Gratwohl; H G Prentice; C Black; A Tyndall
Journal:  Ann Rheum Dis       Date:  2001-06       Impact factor: 19.103

7.  Imbalance of CD4+ lymphocyte subsets in patients with mixed connective tissue disease.

Authors:  H Becker; A Langrock; K Federlin
Journal:  Clin Exp Immunol       Date:  1992-04       Impact factor: 4.330

8.  Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4.

Authors:  A E Postlethwaite; M A Holness; H Katai; R Raghow
Journal:  J Clin Invest       Date:  1992-10       Impact factor: 14.808

9.  Increased CD8+ T cell apoptosis in scleroderma is associated with low levels of NF-kappa B.

Authors:  Aharon Kessel; Itzhak Rosner; Michael Rozenbaum; Devy Zisman; Anca Sagiv; Zehava Shmuel; Edmond Sabo; Elias Toubi
Journal:  J Clin Immunol       Date:  2004-01       Impact factor: 8.317

Review 10.  Effects of immunomodulating therapy in systemic sclerosis.

Authors:  F H van den Hoogen; A M Boerbooms; L B van de Putte
Journal:  Clin Rheumatol       Date:  1990-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.